Interim analysis of the phase III KEYNOTE-811 study led to accelerated approval of pembrolizumab with first-line platinum-based chemotherapy and trastuzumab for HER2-positive gastric cancer on 5 May 2021, irrespective of PD-L1 status [12]. The gene discussed is ERBB2; the disease is gastric cancer.